📊 DARE Key Takeaways
Is Dare Bioscience, Inc. (DARE) a Good Investment?
Dare Bioscience is in severe financial distress with a completely unsustainable business model characterized by $3.0M operating losses against only $152.5K in revenue, resulting in -1967% operating margins. The company is burning $5.5M annually in operating cash flow with only $18.5M cash on hand, providing approximately 3.5 years of runway at current burn rates, while stockholders' equity has collapsed to just $734.5K. Without imminent successful drug commercialization or significant capital injection, the company faces high bankruptcy risk and severe shareholder dilution.
Dare Bioscience’s fundamentals are very weak: revenue has effectively disappeared, losses remain large, and margins are deeply negative, indicating the business is still dependent on external funding rather than self-sustaining operations. The balance sheet is supported by cash and no meaningful long-term debt, but very thin equity, ongoing cash burn, and limited revenue visibility materially weaken financial quality.
Dare Bioscience, Inc. Key Strengths (DARE)
- Maintains $18.5M in cash providing near-term operational runway
- No long-term debt burden limiting financial obligations
- Revenue growth of 10429% YoY demonstrates early product traction
- Cash balance of $23.08M provides near-term operating flexibility
- No meaningful long-term debt reduces balance-sheet leverage risk
- Operating cash burn is significant but still broadly covered by existing cash in the near term
DARE Stock Risks: Dare Bioscience, Inc. Investment Risks
- Operating losses of $3.0M against revenue of $152.5K creates unsustainable -1967% operating margin
- Stockholders' equity of $734.5K is critically depleted; total assets ($27.8M) nearly equal liabilities ($27.1M)
- Operating cash burn of $5.5M annually with only 3.5 years of runway at current burn rate
- Net income deteriorated 230.6% YoY despite revenue growth, indicating worsening unit economics
- Current ratio of 1.03x provides minimal liquidity cushion above insolvency threshold
- Revenue fell 99.7% YoY to nearly zero, showing extremely poor revenue stability and commercialization traction
- Persistent operating and net losses with deeply negative margins indicate no path to profitability is yet visible in reported fundamentals
- Equity of only $2.86M against $27.89M of liabilities leaves limited balance-sheet cushion and raises future dilution or financing risk
Key Metrics to Watch
- Monthly operating cash burn rate and runway extension timeline
- Product revenue contribution and gross margins once products commercialize
- Clinical trial outcomes and regulatory milestones for pipeline candidates
- Customer acquisition cost and customer lifetime value economics
- Financing activities and capital raising to extend runway
- Quarterly operating cash flow and ending cash balance
- Revenue recovery and non-dilutive funding/collaboration income
Dare Bioscience, Inc. (DARE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Dare Bioscience, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
DARE Profit Margin, ROE & Profitability Analysis
DARE vs Healthcare Sector: How Dare Bioscience, Inc. Compares
How Dare Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dare Bioscience, Inc. Stock Overvalued? DARE Valuation Analysis 2026
Based on fundamental analysis, Dare Bioscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dare Bioscience, Inc. Balance Sheet: DARE Debt, Cash & Liquidity
DARE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dare Bioscience, Inc.'s revenue has declined by 90% over the 5-year period, indicating business contraction. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
DARE Revenue Growth, EPS Growth & YoY Performance
DARE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $25.4K | -$3.0M | $-0.21 |
| Q3 2025 | $2.3K | $1.5M | $0.17 |
| Q2 2025 | $4.3K | -$4.0M | $-0.45 |
| Q1 2025 | $9.3K | -$4.4M | $-0.50 |
| Q2 2024 | N/A | $6.2M | $0.72 |
| Q1 2024 | N/A | -$6.8M | $-0.07 |
| Q3 2023 | N/A | $414.0K | $-0.08 |
| Q2 2023 | N/A | $414.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dare Bioscience, Inc. Dividends, Buybacks & Capital Allocation
DARE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dare Bioscience, Inc. (CIK: 0001401914)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DARE
What is the AI rating for DARE?
Dare Bioscience, Inc. (DARE) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DARE's key strengths?
Claude: Maintains $18.5M in cash providing near-term operational runway. No long-term debt burden limiting financial obligations. ChatGPT: Cash balance of $23.08M provides near-term operating flexibility. No meaningful long-term debt reduces balance-sheet leverage risk.
What are the risks of investing in DARE?
Claude: Operating losses of $3.0M against revenue of $152.5K creates unsustainable -1967% operating margin. Stockholders' equity of $734.5K is critically depleted; total assets ($27.8M) nearly equal liabilities ($27.1M). ChatGPT: Revenue fell 99.7% YoY to nearly zero, showing extremely poor revenue stability and commercialization traction. Persistent operating and net losses with deeply negative margins indicate no path to profitability is yet visible in reported fundamentals.
What is DARE's revenue and growth?
Dare Bioscience, Inc. reported revenue of $152.5K.
Does DARE pay dividends?
Dare Bioscience, Inc. does not currently pay dividends.
Where can I find DARE SEC filings?
Official SEC filings for Dare Bioscience, Inc. (CIK: 0001401914) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DARE's EPS?
Dare Bioscience, Inc. has a diluted EPS of $-0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DARE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Dare Bioscience, Inc. has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DARE stock overvalued or undervalued?
Valuation metrics for DARE: ROE of -408.5% (sector avg: 15%), net margin of -1,967.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DARE's AI grade for 2026?
Our dual AI analysis gives Dare Bioscience, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DARE's free cash flow?
Dare Bioscience, Inc.'s operating cash flow is $-5.5M, with capital expenditures of $0.0. FCF margin is -3,621.2%.
How does DARE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,967.7% (avg: 12%), ROE -408.5% (avg: 15%), current ratio 1.03 (avg: 2).